Lv1
58 积分 2021-08-17 加入
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
1个月前
已完结
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
1个月前
已完结
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial
1个月前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
1个月前
已完结
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
2个月前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
4个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
4个月前
已完结
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
6个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
7个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
8个月前
已完结
皖公网安备34019202002308
